JMJeenat Mehareen

Jeenat Mehareen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jeenat Mehareen has a total of 61 co-authors. Here are the top co-authors by number of shared publications:

  • Mohsen Sadatsafavi

    Respiratory Evaluation Sciences Program, Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, Canada

    7 shared publications
  • Don D. Sin

    Centre for Heart Lung Innovation, St. Paul's Hospital, Vancouver, BC, Canada

    3 shared publications
  • Mohsen Sadatsafavi

    Respiratory Evaluation Sciences Program, Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, Canada

    3 shared publications
  • Amin Adibi

    Respiratory Evaluation Sciences Program, Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, Canada

    2 shared publications
  • Don D. Sin

    Centre for Heart Lung Innovation and Division of Respirology, Department of Medicine, University of British Columbia, Vancouver, BC, Canada

    2 shared publications
  • Kayly Choy

    Respiratory Evaluation Sciences Program, Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, Canada

    2 shared publications

Latest Publications

  • Open Access

    ACCEPT 3.0: Recalibrating ACute COPD Exacerbation Prediction Tool (ACCEPT) for global use

    by Laura Huey Mien Lim, Jeenat Mehareen, Amin Adibi, Christer Janson, Pierre-Régis Burgel, Tae Yoon Lee, Hana Müllerová, Della Varghese, Jonathan Marshall, Surya P. Bhatt, et al.

    Background: The ACute COPD Exacerbation Prediction Tool (ACCEPT) is an algorithm for predicting 12-month risk of chronic obstructive pulmonary disease (COPD) exacerbations. To make it suitable for international use, we externally validated and recalibrated ACCEPT 2.0 to incorporate country-specific background exacerbation risk, using multi-country data from NOVELTY (a NOVEL observational longiTudinal studY). Methods: Our study cohort included patients aged $$\:\ge\:$$ 40 years with physician-diagnosed COPD and $$\:\ge\:$$ 30 days of follow-up. We predicted the occurrence of any moderate-to-severe (primary endpoint) and severe (secondary) exacerbations at 12 months, using country-level random effects to account for between-country differences in background exacerbation risks unexplained by predictor effects. We assessed model performance via discrimination, calibration, and net benefit. Results: The analysis sample comprised 5,181 patients (59.4% male, mean age at baseline 66.5 years) from 18 countries, with a mean follow-up of 357 days. 12-month risks ranged between 0.11 and 0.46 (mean = 0.26) for moderate-to-severe and 0.03–0.21 (mean = 0.08) for severe exacerbations. Without country-level adjustment, ACCEPT 2.0’s area under the receiver operating characteristic curve (AUROC) was 0.73 (95% CI 0.72–0.75) and 0.76 (95% CI 0.73–0.78) for moderate-to-severe and severe exacerbations, respectively. However, ACCEPT 2.0 consistently overpredicted risks (observed-to-expected [O/E] risk ratio = 0.57 [95% CI 0.54–0.60] and 0.51 [95% CI 0.46–0.56]). After country-level recalibration, ACCEPT 3.0 showed similar AUROCs (0.75 and 0.76) but substantially improved calibration (O/E ratios: 0.99 [95% CI 0.94–1.05] and 0.99 [95% CI 0.90–1.09]). The net benefit of ACCEPT 3.0 exceeded ACCEPT 2.0 across treatment thresholds of 5%-20%. Conclusion: Recalibrating ACCEPT 2.0 with country-level effects significantly improved calibration of COPD exacerbation risks. The resulting ACCEPT 3.0 is expected to provide higher clinical utility across a range of treatment thresholds.

  • Patient and physician evaluation of digital health decision support tool in COPD care

    by Jeenat Mehareen, Megan Simmons, Phalgun Joshi, Mohsen Sadatsafavi

    Introduction: Digital health technologies that communicate individualized risk information may strengthen shared decision-making in COPD care. As part of a randomized trial evaluating a personalized COPD exacerbation prediction tool, a tailored information sheet was designed to support treatment discussions. We evaluated patients’ perceptions of this sheet and physicians’ usability assessments of the tool. Methods: Patients from two hospitals in British Columbia, Canada, rated the usefulness and adequacy of information across six domains, as well as readability, design, and organization. Physicians completed the System Usability Scale (SUS) and Technology Acceptance Model to assess perceived usefulness (PU) and perceived ease of use (PEOU) of the tool. Results: Among seventy-two participants, <5% reported difficulty reading or understanding the sheet. Most found it well organized (86%), visually appealing (82%), and appropriately formatted (86%). Across domains, 70–90% rated content as useful or very useful, with inhaler technique highest at 97%. Although, 74-89% felt the amount of information was “just right”, 25% thought information on exercise guidance was inadequate. Awareness of smoking cessation and exercise resources varied. Overall, 87% would recommend the sheet to other COPD patients. Physicians (n=6) reported strong acceptance of the tool (mean SUS = 82) with high PU (5.0) and PEOU (6.06). Suggestions for improving the tool included adding biologics information in future and extending it to other chronic respiratory conditions. Conclusions: These findings show the feasibility and acceptability of integrating precision medicine tools with patient-centered communication into routine COPD care.

  • 50-year Trends in Cancer Incidence and Mortality among Adolescents and Young Adults in British Columbia, Canada

    by Jeenat Mehareen, Rachel MacKay Altman, Mary De Vera, Karen Goddard, Fuchsia Howard, X. Joan Hu, Agnes S. Lai, Andrea C. Lo, Helen McTaggart-Cowan, Justin Oh, et al.

    Introduction: Adolescents and young adults (AYAs) with cancer constitute a distinct population with unique biological and survivorship challenges. Long-term, population-based analyses of incidence and mortality trends in AYAs remain limited. Methods: We conducted a retrospective, longitudinal population-based cohort study using data from the Childhood, Adolescent, and Young Adult Cancer Survivor program in British Columbia, Canada, from 1971 to 2020. We analyzed age-standardized incidence rates (ASIR) for the 16 cancer types with the highest incidence and age-standardized mortality rates (ASMR) for the 8 cancer types with the highest mortality, overall and by sex. Trends were evaluated using annual percentage change (APC) and average APC from joinpoint regression analyses. Results: The cohort included 43,588 patients with a first cancer diagnosis and 6825 deaths. From 1971 to 2020, cancer incidence rose overall (AAPC 0.1; 95% confidence interval [CI]: −1.0, 1.3), with a brief decline in the mid-1990s. Significant increases in ASIR were observed for thyroid (APC 1983–2020 : 3.0, 95% CI: 2.4, 3.6) and gastrointestinal cancers (APC 1988–2020 : 1.9, 95% CI: 1.3, 2.6). Female AYAs showed rising trends in Hodgkin and non-Hodgkin lymphoma, while testicular cancer incidence increased among males. Male AYAs had higher all-cause mortality (51.6%). Cancer mortality declined beginning in the early 1990s; however, gastrointestinal cancer mortality increased in males (APC 1990–2020 : 1.7, 95% CI: 0.3, 3.1). Conclusions: Cancer incidence among AYAs has risen over five decades, particularly for thyroid and gastrointestinal cancers, with concerning increases in gastrointestinal cancer mortality among males. These findings emphasize the need for targeted prevention, screening, and intervention strategies.

  • Performance of multivariable risk prediction algorithms in predicting COPD exacerbations: a population-based study

    by Jeenat Mehareen, Laura Huey Mien Lim, Amin Adibi, Joseph Emil Amegadzie, Yuan Xia, Mary A De Vera, Michael R Law, Don D Sin, Surya P Bhatt, Jennifer K Quint, et al.

    Introduction: Efficient preventive management of acute exacerbation of chronic obstructive pulmonary disease (COPD) is predicated on accurate risk stratification. We compared the performance of exacerbation history (current standard of care) versus a revised version of a multivariable risk scoring tool (Acute COPD Exacerbation Prediction Tool (ACCEPT)) using primary-care UK data. Methods: We used validated case definitions to identify diagnosed patients with COPD ≥40 years old from the UK Clinical Practice Research Datalink Aurum (2004–2020). For each patient, a single annual COPD visit was randomly selected as the index date. The outcome was the occurrence of ≥1 moderate/severe exacerbation(s) within a year of the index date. We conducted time-to-event analyses of the latest version of ACCEPT (ACCEPT 2.0) and developed a recalibrated version (ACCEPT 3.0-UK). Model performance was evaluated using discrimination (time-dependent area under the receiver operating characteristic curve (AUC)), calibration and net benefit. Results: The final cohort included 158 384 patients (55.0% male; mean age 71.5 years). ACCEPT 2.0 achieved an AUC of 0.77 for predicting moderate/severe exacerbations, outperforming both any and frequent exacerbator categories (AUC: 0.69 and 0.67, respectively). However, it overpredicted exacerbation events (observed-to-expected (O/E) ratio: 0.81 (95% CI 0.80 to 0.81)). Recalibration resolved this overprediction, yielding O/E ratio of 1.00 (95% CI 0.99 to 1.00), while maintaining discrimination (AUC: 0.77). ACCEPT 3.0-UK was net beneficial and superior to exacerbation history across a wide range of risk thresholds. Conclusion: ACCEPT 3.0-UK has substantially higher performance than exacerbation history, quantifies predicted risks for shared decision-making and is likely to confer clinical utility for risk stratification in primary care.


  • Exacerbations in chronic obstructive pulmonary disease (COPD): Early patterns say much about what is to come

    by Jeenat Mehareen, Mohsen Sadatsafavi

    In patients with chronic obstructive pulmonary disease (COPD), acute exacerbations are watershed moments, putting substantial burden on patients and carrying high risks of morbidity and mortality. ...

  • Open Access

    Optimizing Communication Strategies for COPD Management: Effectiveness of Educational Video and Pamphlet Interventions

    by Jeenat Mehareen, Sharon Zhu, Jim Johnson, Mohsen Sadatsafavi, Erica Frank

    Objectives: Risk prediction models are increasingly used at point of care to support personalized treatment decisions. This study created and evaluated two Information, Education, and Communication (IEC) resources to improve public understanding of a risk prediction tool for Chronic Obstructive Pulmonary Disease (COPD) management. Methods: We created a 5-minute video and a pamphlet explaining the burden of COPD and how a prediction model generates quantitative estimates of, and benefit of certain treatments for, exacerbations of the disease. These tools were tested among students and researchers in public health. A patient partner was engaged throughout to ensure the materials were accessible and patient-centered. Results: Twenty-five individuals participated (80% female; 60% aged 25–64). After reviewing the materials, 92% of participants agreed to the statement “I am familiar with the idea of precision medicine approach”. Most (72%) felt they received sufficient information about the tool, and 92% believed such materials could support patient decision. Participants stated that the materials were clear, detailed, and written in plain language. Participants preferred the pamphlet (68%) over the video (44%). Suggestions for improvement included expanding content on how the tool works. Conclusions: The findings of this study provided a better understanding of how to present complex medical information around precision medicine that is accessible and meaningful to diverse audiences. We will improve our materials based on these comments, and continue to make them available at https://resp.core.ubc.ca/show/patient_committee_2025

  • Factors associated with guideline-concordant maintenance inhaled medication for COPD: a population-based, longitudinal cohort study

    by Yiwei Yin, Jeenat Mehareen, Mohsen Sadatsafavi, Emily Brigham, Mary A De Vera, Kevin I Duan, Kate M Johnson

    Background Despite guideline recommendations, many patients with chronic obstructive pulmonary disease (COPD) do not receive or persist with guideline-concordant maintenance inhaled medications. We examined patient and health system factors associated with guideline concordance and persistence. Methods We conducted a population-based cohort study using administrative data from British Columbia, Canada (2011–2022). Patients aged ≥40 years with newly diagnosed COPD were included. Patients were classified as having high risk (≥2 outpatient or ≥1 inpatient exacerbation in the prior year) or low risk (≤1 outpatient exacerbation) of exacerbations, which we used to determine whether dispensed medications were concordant with guidelines. We used separate generalised linear models to evaluate the association between patient, clinical and health system factors and the initiation of guideline-concordant medications and subsequent persistence. Results We included 71 996 patients with a mean follow-up of 6.15 years (SD 2.65). 30.42% of patients initiated guideline-concordant treatment. Among those who initiated, the mean proportion of days covered (PDC) by guideline-concordant regimens was 31.93%. Patients at high risk of exacerbations initiated guideline-concordant regimens more often than those at low risk (mean 70.4% vs 13.3%) and had a higher mean PDC (57.33% vs 26.35%) per patient-year. Pulmonologist care and additional outpatient visits increased both initiation (OR 5.14, 95% CI 4.88 to 5.41 and OR 1.25, 95% CI 1.24 to 1.26, respectively) and persistence (OR 1.13, 95% CI 1.09 to 1.17 and OR 1.019, 95% CI 1.015 to 1.024, respectively) with guideline-concordant medications. Conclusion Guideline-concordant use of maintenance inhaled medications is low. Increased access to outpatient and specialist care may support COPD management.


  • Open Access

    Trends and Regional Differences in the Use of Maintenance Inhaled Medications in COPD: A Population-Based Study

    by Jeenat Mehareen, Yiwei Yin, Kayly Choy, Kate M. Johnson, Don D. Sin, Mohsen Sadatsafavi


  • Open Access

    Regional Variations in Burden of Chronic Obstructive Pulmonary Disease

    by Jeenat Mehareen, Kayly Choy, Yiwei Yin, Don D. Sin, Mohsen Sadatsafavi

    Background: Chronic Obstructive Pulmonary Disease (COPD) imposes a significant burden on individuals and communities. While differences in such burden are often studied across countries and healthcare systems, differences within jurisdictions have not been well evaluated. The aim of this study was to assess the trends of, and factors explaining, regional variability in the burden of COPD within a well-defined population with publicly funded healthcare system. Methodology: We used population-based health records of people aged 35 years or older diagnosed with COPD across the 16 health regions of British Columbia, Canada (2010–2020). The primary outcomes were prevalence, incidence, all-cause hospital admissions, and all-cause mortality, while secondary outcomes were COPD- and cardiovascular disease (CVD)-specific hospitalization and mortality. We used generalized linear models to examine how outcomes varied by regions and changed over time, controlling for sex, age, socioeconomic status, and rural/urban residence. Results: Over the 11-year study period, there were 312,014 individuals diagnosed with COPD (48.1% female, mean baseline age: 68.2 years). Across the province, standardized prevalence and all-cause mortality remained relatively stable during the study period, whereas incidence and all-cause hospitalization declined. There were up to a three-fold difference in standardized incidence and prevalence, and up to a two-fold difference in standardized all-cause hospitalization and mortality across regions (all p<0.05). These differences remained significant after controlling for case mix. Among COPD patients, both CVD-specific hospitalization and mortality were higher compared to COPD-specific hospitalization and mortality. Conclusion: Despite being governed by the same universal healthcare system, difference in burden of COPD across geographic regions in this Canadian province was significant. Heterogeneity was more prominent in incidence and prevalence, compared with hospitalization and mortality, suggesting that the variation in the process of care leading to diagnosis is more substantial than variation in COPD outcomes.